A data.frame with a design and proteomic data.
data(MS)Ellen Færgestad Mosleth
Data from biobank are analysed a study population of 101 patients, 37 were diagnosed with multiple sclerosis, and 64 without multiple sclerosis. Of the patients without multiple sclerosis, 50 were diagnosed with other neurological disorders and 14 were neurologically healthy patients who had undergone spinal anaesthesia for orthopaedic surgery on the knee or ankle, i.e. neurologically healthy controls. Unless otherwise stated, all the patients without multiple sclerosis were considered as controls for this study. All patients with multiple sclerosis had relapsing remitting multiple sclerosis. The proteome were obtained on cerebrospinal fluid samples from all patients prior medical treatment for multiple sclerosis. It was discovered the patients separated into two clusters, called cluster 1 and cluster 2. This is utilised in the data analysis by considering the data as 2-way factorial design with the two factors: MS and clusters both on two levels.
* Opsahl, J.A. et al. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics 16, 1154-1165 (2016).
* Ellen Færgestad Mosleth, Christian Alexander Vedeler, Kristian Hovde Liland, Anette McLeod, Gerd Haga Bringland, Liesbeth Kroondijk, Frode Berven, Artem Lysenko, Christopher J. Rawlings, Karim El-Hajj Eid, Jill Anette Opsahl, Bjørn Tore Gjertsen, Kjell-Morten Myhr and Sonia Gavasso, Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. Scientific Reports – Nature 11(4087), (2021).